Most of us will be staying away from other people and in our homes for the next several weeks (at least), but in addition to taking a stroll outside (staying appropriately distanced from others), there are some great virtual activities you can partake in online. Many public libraries have gone digital; you can become a...Read More
The FDA workshop on “The Development of Antibiotics for the Treatment of NTM Disease” on April 8, 2019 was very successful, with more than 100 people attending in person. The agenda focused on issues surrounding clinical trials and the development of a validated Patient-Reported Outcome (PRO) tool. Panelists included experts in NTM and in PRO,...Read More
On April 8th, 2019 the U.S. Food & Drug Administration will host a public workshop on the development of antibacterial drugs for the treatment of nontuberculous mycobacterial (NTM) infection. At this workshop, we will convey patient experiences and preferences. Ahead of the workshop, we have published a survey to gather more information about patient preferences....Read More
The Food and Drug Administration is convening a public workshop titled “Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis” on Wednesday, June 27th from 8:30pm to 4:30pm ET. The purpose of this workshop is to discuss the clinical trial design challenges and future considerations for inhaled antibacterial products to treat cystic...Read More
WHAT IS NTM?
“NTM” is short for Nontuberculous Mycobacteria. NTM disease is a serious chronic lung illness.